Go to content
DSM B.V.

DSM B.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 20 dec 2005 - 08:09
Statutaire naam DSM B.V.
Titel Crucell and DSM further strengthen and expand the development of PER.C6® Protein and Monoclonal Antibody Licensing Business Joint R&D center to be established on US East Coast and in the Netherlands
Bericht Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products (a business group of Royal DSM NV) announced today that they will strengthen and expand the development of the PER.C6® protein and monoclonal antibody licensing business. The two companies will create an integrated solution for the production of recombinant proteins and monoclonal antibodies on PER.C6® in order to increase licensing and royalty income and accelerate the development and roll-out of the PER.C6® technology platform in the market.

Datum laatste update: 18 februari 2025